Biopharmaceutical business AstraZeneca will drive its on-market growth platforms to return to growth as it moves through a period of patent expiries and revenue declines, an update issued by the group has shown.
It said that it would progress its Phase II pipeline, which has the potential to double Phase III asset volume by 2016 and outlined plans to launch a flow of speciality care products, balancing the company's historic strength in primary care.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
‘Inheritance tax insurance’ enquiries are soaring – but is it worth it?Premiums for whole of life insurance can run to £5,000 a month to cover a £300,000 inheritance tax bill, with policies costing more the older you take them out.
-
MPs warn over Lifetime ISAs which could leave savers out of pocketThe Treasury Committee has highlighted confusion around the Lifetime ISA withdrawal charge, which risks consumers losing “a significant part of their savings”
